These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3132386)

  • 1. Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species.
    Spitzer ED; Travis SJ; Kobayashi GS
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):80-1. PubMed ID: 3132386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of in vitro antifungal activity of LY121019.
    Hobbs M; Perfect J; Durack D
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):77-80. PubMed ID: 3132385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B.
    Meunier F; Lambert C; Van der Auwera P
    J Antimicrob Chemother; 1989 Sep; 24(3):325-31. PubMed ID: 2681118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents.
    Pfaller MA; Wey S; Gerarden T; Houston A; Wenzel RP
    Diagn Microbiol Infect Dis; 1989; 12(1):1-4. PubMed ID: 2714066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fungicidal activity of cilofungin (LY121019) alone and in combination with anticapsin or other antifungal agents.
    Pfaller M; Gordee R; Gerarden T; Yu M; Wenzel R
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):564-7. PubMed ID: 2504601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019.
    Pfaller MA; Gerarden T; Yu M; Wenzel RP
    Diagn Microbiol Infect Dis; 1988 Sep; 11(1):1-9. PubMed ID: 3219817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.
    Smith KR; Lank KM; Dismukes WE; Cobbs CG
    Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):588-92. PubMed ID: 1655435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis.
    Hall GS; Myles C; Pratt KJ; Washington JA
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1331-5. PubMed ID: 3058017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro antifungal susceptibility studies with 30 serotype A and B isolates of Candida albicans.
    Shadomy S; Shadomy HJ
    Diagn Microbiol Infect Dis; 1991; 14(1):21-2. PubMed ID: 2013207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of cilofungin (LY121019) against Candida species in vitro.
    Odds FC
    J Antimicrob Chemother; 1988 Dec; 22(6):891-7. PubMed ID: 3243737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic.
    Gordee RS; Zeckner DJ; Howard LC; Alborn WE; Debono M
    Ann N Y Acad Sci; 1988; 544():294-309. PubMed ID: 3063174
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro and in vivo anti-Candida activity and toxicology of LY121019.
    Gordee RS; Zeckner DJ; Ellis LF; Thakkar AL; Howard LC
    J Antibiot (Tokyo); 1984 Sep; 37(9):1054-65. PubMed ID: 6389460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antifungal susceptibility among the isolates of yeast from the University Hospital of the Ryukyus].
    Ohta C; Yamane N; Nakasone I; Onaga S; Nakamura K
    Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 2005; 16(2):127-33. PubMed ID: 16536058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
    Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
    Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
    Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
    J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of the antifungal activity of LY121019, a new echinocandin derivative.
    Strippoli V; D'Auria FD; Simonetti N
    Chemioterapia; 1988 Feb; 7(1):33-7. PubMed ID: 3288366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro effects of cilofungin (LY121019), amphotericin B and amphotericin B-deoxycholate on human polymorphonuclear leucocytes.
    Van der Auwera P; Meunier F
    J Antimicrob Chemother; 1989 Nov; 24(5):747-63. PubMed ID: 2557318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of LY121019 against Candida species and Torulopsis glabrata.
    Picard M; Meshulam T; Sugar AM
    Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):432-3. PubMed ID: 3137054
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species.
    Valentín A; Cantón E; Pemán J; Fernandez-Rivero ME; Tormo-Mas MA; Martínez JP
    J Antimicrob Chemother; 2016 Dec; 71(12):3449-3452. PubMed ID: 27543657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.
    Karlowsky JA; Hoban DJ; Zhanel GG; Goldstein BP
    Int J Antimicrob Agents; 2006 Feb; 27(2):174-7. PubMed ID: 16414247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.